MAPT and Alzheimer disease: MCI also constitutes a suitable stage to assess effects of disease-modifying treatments and recent clinical trials have focused on MCI and early AD.40,41 By highlighting the potential of tau PET as a tool to determine who will likely progress among an unselected cohort of individuals with MCI, our findings substantiate the utility of tau PET as a disease-monitoring tool in clinical trials.